CA-ASM-GLOBAL
Today, The Rolling Stones have announced they will be extending the STONES TOUR ’24 HACKNEY DIAMONDS with an additional stop in Ridgedale, Missouri, on July 21 at Thunder Ridge Nature Arena. Tickets are on sale Friday, May 31, 2024, at 10 a.m. local time. For ticketing information, please visit www.rollingstones.com.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523672007/en/
(Graphic: Business Wire)
Mick, Keith and Ronnie kicked off their wildly anticipated tour in Houston, Texas, last month and have brought their legendary show to cities across the United States, including the New Orleans Jazz and Heritage Festival, treating fans to their iconic hits and new music from their critically acclaimed new album HACKNEY DIAMONDS. The STONES TOUR ‘24 HACKNEY DIAMONDS will make stops in 12 more cities across the U.S. and Canada with stops in East Rutherford, Foxboro, Orlando, Atlanta, Philadelphia, Cleveland, Denver, Chicago, Vancouver, Los Angeles and Santa Clara with a final stop in Ridgedale. Full tour routing is below.
Hackney Diamonds is their first studio set of new material since 2005’s A Bigger Bang. Since then, the Stones have continued to smash box office records on a series of global sell-out tours and released 2016’s GRAMMY® Award winning Blue & Lonesome, which featured their brilliant versions of many of the blues tracks that helped shape their sound and topped album charts around the world. In 2022, they thrilled European audiences totaling nearly a quarter of a million on the anniversary Sixty tour. The Rolling Stones have sold over 250 million albums worldwide.
Thunder Ridge Nature Arena — a decade in planning, development and construction with the ambition to create America’s most beautiful outdoor amphitheater — is scheduled to open this May as a one-of-a-kind immersive outdoor “musical postcard from Mother Nature.” Located in Ridgedale, Missouri, just a few miles from Branson, Thunder Ridge Nature Arena is described by its creator and visionary — noted conservationist and Bass Pro Shops founder Johnny Morris as a “gift of the Ozarks to the world.” It is the only venue on Earth completely dedicated to conservation.
AEG Presents’ Concerts West is the promoter of the Stones Tour ’24 Hackney Diamonds. For tickets and information, head to www.rollingstones.com.
THE ROLLING STONES – STONES TOUR ‘24 HACKNEY DIAMONDS
Sponsored by AARP
Thursday, May 23, 2024 |
MetLife Stadium |
East Rutherford, NJ |
Sunday, May 26, 2024 |
MetLife Stadium |
East Rutherford, NJ |
Thursday, May 30, 2024 |
Gillette Stadium |
Foxboro, MA |
Monday, June 3, 2024 |
Camping World Stadium |
Orlando, FL |
Friday, June 7, 2024 |
Mercedes-Benz Stadium |
Atlanta, GA |
Tuesday, June 11, 2024 |
Lincoln Financial Field |
Philadelphia, PA |
Saturday, June 15, 2024 |
Cleveland Browns Stadium |
Cleveland, OH |
Thursday, June 20, 2024 |
Empower Field at Mile High |
Denver, CO |
Thursday, June 27, 2024 |
Soldier Field |
Chicago, IL |
Sunday, June 30, 2024 |
Soldier Field |
Chicago, IL |
Friday, July 5, 2024 |
BC Place |
Vancouver, BC |
Wednesday, July 10, 2024 |
SoFi Stadium |
Los Angeles, CA |
Saturday, July 13, 2024 |
SoFi Stadium |
Los Angeles, CA |
Wednesday, July 17, 2024 |
Levi’s® Stadium |
Santa Clara, CA |
Sunday, July 21, 2024 |
Thunder Ridge Nature Arena |
Ridgedale, MO |
www.youtube.com/user/therollingstones
www.instagram.com/therollingstones
www.tiktok.com/@therollingstones
www.facebook.com/therollingstones
www.twitter.com/rollingstones
www.aegpresents.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523672007/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
